Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 20 November 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Barrett's esophagus and H pylori as prognosis for GERD

H pylori infection has a positive influence on healing in patients with erosive reflux disease and coexistent Barrett's esophagus but no influence on those without Barrett's esophagus, finds the latest issue of Gut.

News image

fiogf49gjkf04

Adequacy of acid suppression is a critical factor influencing healing in gastro-esophageal reflux disease (GERD).

The European prospective study ProGERD was set up to determine the endoscopic and symptomatic progression of GERD over 5 years under routine care, after initial acid suppression with esomeprazole.

Dr Malfertheiner and colleagues report on factors influencing endoscopic healing and symptom resolution during the acute treatment phase.

The research team obtained biopsies from the esophagus of patients with symptoms suggestive of GERD who underwent endoscopy.

The team used the information obatined from the biopsied for diagnosis of abnormalities, including Barrett’s esophagus.

Age, sex, and body mass index appear to have no significant impact on healing
Gut

The researchers included data from 6215 patients in the ‘intention to treat’ analysis.

The investigators reported that 3245 patients were diagnosed as having erosive reflux disease and 2970 non-erosive reflux disease.

Patient with erosive reflux disease patients were treated with esomeprazole 40 mg for 4 to 8 weeks for endoscopic healing.

The team reported that patients with non-erosive reflux disease received 20 mg esomeprazole for 2 to 4 weeks for resolution of heartburn symptoms.

The team found that endoscopic healing occurred overall in 88% of erosive reflux disease patients.

Endoscopic healing was significantly lower at 77% in those with more severe oesophagitis and at 73% in those with Barrett’s esophagus.

The researchers noted that endoscopic healing was particularly lower at 70% in Helicobacter pylori negative patients with Barrett’s esophagus.

The investigators observed that age, sex, and body mass index appeared to have no significant impact on healing.

Complete heartburn resolution was reported by 70% of erosive reflux disease patients and by 65% of non-erosive reflux disease patients at the last visit.

In addition, the team found that only H pylori infection had a significant influence on complete heartburn resolution in the non-erosive reflux disease group.

Dr Malfertheiner’s team concludes, “The presence of Barrett’s mucosa, as well as severe mucosal damage, exerts a negative impact on healing.”

H pylori infection had a positive influence on healing in patients with erosive reflux disease and coexistent Barrett’s esophagus but no influence on those without Barrett’s esophagus.”

Gut 2005: 54: 746-751
16 May 2005

Go to top of page Email this page Email this page to a colleague

 20 November 2017 
Barriers to hepatitis C treatment
 20 November 2017 
Socioeconomic characteristics in diverticular disease
 20 November 2017 
Endoscopic indices of disease activity for Crohn’s
 17 November 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 17 November 2017 
PPI use and cognitive function in women
 17 November 2017 
Predicting microscopic colitis
 16 November 2017 
NAFLD-hepatocellular carcinoma and survival after orthotopic liver transplant
 16 November 2017 
Prepregnancy obesity and severe maternal morbidity
 16 November 2017 
Celiac disease screening in adult first-degree relatives
 15 November 2017 
Breastfeeding and the risk of IBD
 15 November 2017 
Medication nonadherence and health care costs
 15 November 2017 
Predicting recurrence after curative rectal cancer surgery
 14 November 2017 
HBV/HCV coinfection and cirrhosis
 14 November 2017 
Sexual dysfunction after rectal cancer surgery
 14 November 2017 
Eosinophilic gastroenteritis and colitis
 13 November 2017 
GI bleeding in patients taking non–vitamin K antagonist oral anticoagulants
 13 November 2017 
Genetic polymorphisms, fatty acids and ulcerative colitis
 13 November 2017 
Flares after immunomodulator withdrawal in Crohn's
 10 November 2017 
Thiopurines vs TNF and lymphoma risk in IBD
 10 November 2017 
Drug monitoring of anti-tumour necrosis factor therapy in IBD
 10 November 2017 
Treatment decisions for older patients with colorectal cancer
 09 November 2017 
Quality standards in upper gastrointestinal endoscopy
 09 November 2017 
Irradiated rectal cancer and chemoradiotherapy
 09 November 2017 
Environmental factors and IBD
 08 November 2017 
Prophylaxis of spontaneous bacterial peritonitis
 08 November 2017 
Optimal management of postoperative Crohn's disease
 07 November 2017 
Community Screening for Helicobacter pylori
 07 November 2017 
Early readmission in IBD patients
 07 November 2017 
Mesocolic excision for colon cancer
 06 November 2017 
Food elimination diet for children with eosinophilic esophagitis
 06 November 2017 
Biologic agents and obesity in children with IBD
 06 November 2017 
Liver cancer burden despite extensive use of antiviral agents
 03 November 2017 
Statins and mortality in chronic viral hepatitis
 03 November 2017 
Propofol for outpatient colonoscopy
 03 November 2017 
Asthma and IBD development
 02 November 2017 
Diverticulitis and emergency department burden
 02 November 2017 
Rural residence and risk of IBD
 02 November 2017 
Sexual functioning in Hep C
 01 November 2017 
Heartburn relief in adolescents with GERD
 01 November 2017 
Autoimmune pancreatitis in children
 31 October 2017 
Follow-up of positive results on fecal blood tests
 31 October 2017 
Surveillance in ulcerative colitis and Crohn’s disease
 30 October 2017 
Local recurrence after curative rectal cancer surgery
 30 October 2017 
Low-flow ascites pump in refractory cirrhosis
 30 October 2017 
Medical therapy of patients with pediatric-onset IBD
 27 October 2017 
NAFLD in advanced fibrosis in the USA
 27 October 2017 
Early readmission in cirrhosis after bacterial infections
 26 October 2017 
Predicting response to anti-TNF therapy in Crohn's
 26 October 2017 
Conversion to open laparotomy in rectal cancer
 25 October 2017 
Conversion of colonoscopy to sigmoidoscopy
 25 October 2017 
Fecal microbiota transplantation
 25 October 2017 
Rifaximin and survival in hepatic encephalopathy
 24 October 2017 
Eosinophilic esophagitis with swallowed topical corticosteroids
 24 October 2017 
Meta-analysis in nutritiona research
 23 October 2017 
NAFLD-related hepatocellular carcinoma in liver resection
 23 October 2017 
Outcome of hepatic sarcoidosis
 20 October 2017 
Conversion of planned colonoscopy to sigmoidoscopy
 20 October 2017 
Hospital readmissions reduction program
 19 October 2017 
Surgical anastomosis at 1-year colorectal cancer surveillance
 19 October 2017 
Fecal immunochemical tests in colorectal cancer screening

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us